Article
Author(s):
Even after the tremendous victory won by the American Lithotripsy Society and the Urology Society of America last year in federal court, urologists still must be concerned with Stark II and the federal anti-kickback statute.
Anktiva as a lymphocyte rescue molecule: Unlocking the power of NK cells and T cells
Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC
FDA awards orphan drug, rare pediatric disease designations to ABO-101 for PH1
Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
FDA Updates in Urology: January 2025
Phase 2 trial launches of opaganib plus darolutamide in mCRPC